Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
Crescent Biopharma, Inc. is conducting a primary offering of 8,094,793 ordinary shares and 525,897 pre-funded warrants to purchase ordinary shares at $14.50 per share and $14.499 per pre-funded warrant, for a public offering size of $124,999,479. Underwriters hold a 30-day option to buy up to 1,293,103 additional ordinary shares.
The company expects net proceeds of approximately $115.9 million (or $133.5 million if the option is fully exercised), to fund clinical development of oncology candidates CR-001, CR-002 and CR-003, CMC activities, preclinical programs, and general corporate purposes. Net tangible book value per share will rise from $6.67 to $8.40, implying dilution of $6.10 per new share at the offering price. Management preliminarily estimates cash and cash equivalents of approximately $171.6 million as of June 30, 2026, and believes existing cash plus this raise will fund projected needs into the second half of 2028.
Crescent Biopharma, Inc. provides a preliminary estimate that cash and cash equivalents were approximately $171.6 million as of June 30, 2026. The figure is unaudited, based on management estimates for the quarter, and may change after completion of financial closing procedures.
The company states that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled or applied procedures to this data. The information is treated as filed under Section 18 of the Exchange Act and incorporated by reference into certain securities law filings, and is accompanied by forward-looking statement cautions.
Crescent Biopharma, Inc. is raising capital through a public offering of ordinary shares and pre-funded warrants under an effective shelf registration. The company is a clinical-stage oncology business developing its lead bispecific antibody CR-001 and antibody-drug conjugates CR-002 and CR-003 in Phase 1/2 trials.
The offering consists of newly issued ordinary shares listed on Nasdaq Capital Market under “CBIO” and, in lieu of shares for some investors, pre-funded warrants priced at the share offering price minus $0.001, with a $0.001 exercise price. The warrants are exercisable at any time until fully exercised, subject to ownership caps, but will not be listed and may be illiquid.
As of June 30, 2026, Crescent estimates cash and cash equivalents of approximately $171.6 million and expects existing cash, before this raise, to fund operations into 2028. Net proceeds are intended to support clinical development of CR-001, CR-002 and CR-003, chemistry and manufacturing activities, preclinical research, and general corporate purposes. Investors face immediate and substantial dilution, with additional potential dilution from extensive outstanding options, warrants, preferred shares and a $200 million at-the-market program, alongside risks specific to the pre-funded warrants and complex U.S. tax treatment.
Crescent Biopharma, Inc. filed a shelf registration to offer up to $500,000,000 of securities and a sales agreement prospectus to sell up to $200,000,000 of ordinary shares under an Open Market Sale agreement with Jefferies LLC.
The $200 million sales agreement amount is included in the $500 million shelf; offerings are subject to completion and may be sold from time to time in one or more offerings. The prospectus notes the company’s ordinary shares trade on Nasdaq under the symbol CBIO, with a last reported sale price of $18.00 per share on June 30, 2026.
CRESCENT BIOPHARMA, INC. officer Ryan Lynch reported an open-market sale of 465 Ordinary Shares on June 22, 2026 at a weighted average price of $17.99 per share. These shares were automatically sold to satisfy tax withholding obligations tied to the settlement of restricted stock units granted on December 15, 2025, under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026. Following this tax-related sale, Lynch directly holds 13,871 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Scientific Officer Jan Pinkas reported an open-market sale of 1,288 Ordinary Shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to cover tax withholding obligations arising from the settlement of previously granted restricted stock units.
The sale was executed under a pre-arranged Rule 10b5-1 instruction adopted on February 26, 2026, indicating it was planned in advance specifically to pay taxes on vesting rather than a discretionary portfolio decision. Following the transaction, Pinkas directly holds 22,239 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Financial Officer Richard William Scalzo reported an open-market sale of 1,112 ordinary shares at a weighted average price of $17.99 per share. According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations tied to vested restricted stock units granted on December 15, 2025.
The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, solely to cover taxes from the RSU vesting. After this transaction, Scalzo directly holds 20,298 ordinary shares, indicating he retains a substantial equity position in the company.
CRESCENT BIOPHARMA, INC. officer Barbara Harlin Bispham reported an automatic sale of 1,218 Ordinary Shares on June 22, 2026 to cover taxes from restricted stock units vesting. The weighted average sale price was $17.99 per share, with individual trades ranging from $16.88 to $18.86. These transactions were executed under a pre-arranged Rule 10b5-1 instruction solely to satisfy tax withholding obligations. After the sale, she directly holds 19,330 Ordinary Shares.
CRESCENT BIOPHARMA, INC. Chief Medical Officer Ellie Eunkyung Im reported an open-market sale of 1,219 Ordinary Shares at a weighted average price of $17.99 per share. The footnotes explain these shares were automatically sold to satisfy tax withholding obligations tied to the vesting of restricted stock units.
The sales were executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, and were intended solely to cover taxes from the RSU settlement. After this transaction, the reporting person directly holds 22,069 Ordinary Shares.